Recent advances in primary CNS lymphoma

Current Opinion in Oncology

Volumn 16, Issue 6, 2004, Pages 601-606

  Hoang Xuan, Khê ^a   Camilleri Broët, Sophie ^b   Soussain, Carole ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c CENTRE HOSPITALIER DE MEAUX   (France)

Author keywords

Biology; Chemotherapy; Neurotoxicity; Primary CNS lymphoma; Rituximab

Indexed keywords

METHOTREXATE; RITUXIMAB; TEMOZOLOMIDE; TOPOTECAN;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHILL; HUMAN; NAUSEA; NEUROTOXICITY; PARAPLEGIA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY;

ANTIMETABOLITES, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA; METHOTREXATE; RADIOTHERAPY, ADJUVANT;

EID: 8344253623     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000142927.88773.7e     Document Type: Review

References (37)

1. De Angelis LM, Yahalom J, Thaler HT, et al.: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992, 10:635-643.
2. Olson JE, Janney CA, Rao RD, et al.: The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002, 95:1504-1510.
3. Kadan-Lottick NS, Skluzacek MC, Gurney JG: Decreasing incidence rates of primary central nervous system lymphoma. Cancer 2002, 95:193-202.
4. Anthony IC, Crawford DH, Bell JE: B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas. Brain 2003, 126:1058-1067.
5. Montesinos-Rongen M, Besleaga R, et al.: Absence of Simian Virus 40 DNA sequences in primary central nervous system lymphoma in HIV-negative patients. Virchows Arch 2004, 444:436-438.
6. Weber T, Weber RG, Kaulich K, et al.: Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol 2000, 10:73-84.
7. Nakamura M, Kishi M, Sakaki T, et al.: Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 2003, 63:737-741. An extensive LOH mapping of 6q in a series of 29 PCNSL refined the location of the putative tumor suppressor gene in a small region on 6q22-q23. The PTPRK gene located in this region is a strong candidate gene.
8. Montesinos-Rongen M, Akasaka T, Zuhlke-Jenisch R, et al.: Molecular characterization of BCL6 breakpoints in primary diffuse large B-cell lymphomas of the central nervous system identifies GAPD as novel translocation partner. Brain Pathol 2003, 13:534-538.
9. Linnebank M, Schmidt S, Kolsch H, et al.: The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. Br J Cancer 2004, 90:1969-1971.
10. Harada K, Nishizaki T, Kubota H, et al.: Distinct primary central nervous system lymphoma defined by comparative genomic hybridization and laser scanning cytometry. Cancer Genet Cytogenet 2001, 125:147-150.
11. Fujii A, Ohshima K, Hamasaki M, et al.: Differential expression of chemokines, chemokine receptors, cytokines and cytokine receptors in diffuse large B cell malignant lymphoma. Int J Oncol 2004, 24:529-538.
12. Smith JR, Braziel RM, Paoletti S, et al.: Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003, 101:815-821.
13. Montesinos-Rongen M, Van Roost D, Schaller C, et al.: Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004, 103:1869-1875. The authors demonstrated aberrant somatic hypermutation at high frequency in the proto-oncogenes PIM1, cMYC, RhoH/TTF, PAX5 genes in a series of 10 HIV-negative PCNSL. The mean mutation frequency was increased two- to fivefold compared with extracerebral diffuse large B-cell lymphoma.
14. Ferreri AJ, Blay JY, Reni M, et al.: Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003, 21:266-272.
15. Bessell EM, Graus F, Lopez-Guillermo A, et al.: Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys 2004, 59:501-508.
16. Bessell EM, Lopez-Guillermo A, Villa S, et al.: Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002, 20:231-236.
17. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al.: High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003, 21:4483-4488.
18. Harder H, Holtel H, Bromberg JE, et al.: Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004, 62:544-547. A neuropsychological evaluation of 19 young patients in remission after combined treatment. This study showed an unexpected high rate of cognitive dysfunctions in this population usually considered to be less exposed to neurotoxicity.
19. Pels H, Schmidt-Wolf IG, Glasmacher A, et al.: Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003, 21:4489-4495. The largest prospective multicenter trial to date published (65 patients) evaluating MTX-based chemotherapy with deferred radiotherapy in PCNSL.
20. Batchelor T, Carson K, O'Neill A, et al.: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003, 21:1044-1049. A multicenter phase II trial including 25 patients evaluating high-dose MTX as single agent in newly diagnosed PCNSL. The relatively short progression-free survival reported suggests that adding other agents to MTX is needed to enhance the efficacy of chemotherapy, especially in a chemotherapy-alone strategy.
21. Ferreri AJ, Guerra E, Regazzi M, et al.: Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004, 90:353-358.
22. Abrey LE, DeAngelis LM, Yahalom J: Long term survival in primary CNS lymphoma. J Clin Oncol 1998, 16:859-863.
23. Fliessbach K, Urbach H, Helmstaedter C, et al.: Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 2003, 60:563-568. A longitudinal neuropsychometric evaluation of 10 long survivors after chemotherapy as sole initial treatment, showing an excellent preservation of their cognitive functions.
24. Correa DD, DeAngelis LM, Shi W, et al.: Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004, 62:548-555. A neuropsychological evaluation of 28 patients in disease remission (10 patients treated with chemotherapy alone versus 18 patients with whole brain RT associated or not with chemotherapy). Patients treated with chemotherapy alone displayed significantly less impaired performance in the memory and executive domain than did the patients who received whole-brain RT.
25. Lai R, Abrey LE, Rosenblum MK, et al.: Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004, 62:451-456. A series of five autopsy cases who died of treatment-related leukoencephalopathy after combined therapy. Small-vessel abnormalities that were constantly found suggest that a vascular process may be an important component of this white matter injury.
26. Hoang-Xuan K, Chinot O, Taillandier L: Treatment of primary CNS lymphoma in the elderly. Semin Oncol 2003, 30(suppl 19):53-57.
27. Hoang-Xuan K, Taillandier L, Chinot O, et al.: Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003, 21:2726-2731. A multicenter phase II trial devoted specifically to older patients (50 patients). High-dose MTX-based chemotherapy alone represents a good approach in the elderly to achieve effective tumor control while reducing considerably the risk of delayed neurotoxicity.
28. Reni M, Mason W, Zaja F, et al.: Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 2004, 40:1682-1688.
29. Fischer L, Thiel E, Klasen HA, et al.: Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 2004, 62:1885-1887.
30. Tyson RM, Siegal T, Doolittle ND, et al.: Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma 2003, 44:627-633.
31. Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM, et al.: Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 2003, 219-224.
32. Soussain C, Suzan F, Hoang-Xuan K, et al.: Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001, 19:742-749. The first study showing promising activity of high-dose chemotherapy with autologous stem-cell rescue as salvage therapy in relapsing or refractory PCNSL.
33. Abrey LE, Moskowitz CH, Mason WP, et al.: Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003, 21:4151-4156. A prospective study evaluating high-dose chemotherapy with autologous stem-cell rescue in PCNSL as first-line therapy.
34. Cheng T, Forsyth P, Chaudhry A, et al.: High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003, 31:679-685.
35. Schulz H, Pels H, Schmidt-Wolf I, et al.: Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004, 89:753-754. The authors reported their experience using direct intraventricular/intrathecal administration of rituximab (10 to 40 mg) in a series of six patients. An objective response was achieved only in the patients with a leptomeningeal disease but not in the case of parenchymal tumors.
36. Rubenstein JL, Combs D, Rosenberg J, et al.: Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003, 101:466-468.
37. Wong ET, Tishler R, Barron L, et al.: Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004, 101:139-145.